AbbVie Announces International Skyrizi Approval

19/04/2019 iData Research

Register to receive a free Global Immunology Drugs Market Report Suite report synopsis and brochure The Japan Ministry of Health, Labour and Welfare has recently approved AbbVie’s Skyrizi for trea... Read More

Will Humira Competitors Take Over the Immunology Drugs Market?

18/06/2018 iData Research

Register to receive a free Global Immunology Drugs Market Report Suite 2018-2024 report synopsis and brochure In a new series of reports by iData Research, it was revealed that in 2017, the ... Read More

Biosimilars – A Game Changer in the Immunology Rheumatoid Arthritis Market

17/10/2017 iData Research

Biosimilars are, as the name would suggest, highly similar and are a more affordable alternative to biologics that is poised to influence the current dynamics of the immunology market. ... Read More

AbbVie, Johnson & Johnson Lead US Immunology Drug Market Due to High Cost of Biologic Treatments

17/10/2017 iData Research

The U.S. immunology drug market is expected to grow to $68 billion by 2023 due to the entry of new biosimilars and JAK inhibitors.... Read More

AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Amgen Allowing Commercialization Of AMGEVITA™

05/10/2017 iData Research

Agreements Provide Non-Exclusive License to Amgen for HUMIRA-Related Intellectual Property in the U.S. Effective Jan. 31, 2023, And in Other Markets on Different Dates... Read More

Samsung, Biogen version of AbbVie’s Humira approved in Europe

14/09/2017 iData Research

The new drug, Imraldi, marks the third European Commission approval for “biosimilar” versions from the joint venture, Samsung Bioepis, of drugs in a class known as TNF inhibitors.... Read More